Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Common Equity (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Common Equity data on record, last reported at $64.6 million in Q4 2025.

  • For Q4 2025, Common Equity fell 77.57% year-over-year to $64.6 million; the TTM value through Dec 2025 reached $64.6 million, down 77.57%, while the annual FY2025 figure was $64.6 million, 77.57% down from the prior year.
  • Common Equity reached $64.6 million in Q4 2025 per SNDX's latest filing, down from $115.4 million in the prior quarter.
  • Across five years, Common Equity topped out at $554.2 million in Q4 2023 and bottomed at $64.6 million in Q4 2025.
  • Average Common Equity over 5 years is $323.7 million, with a median of $360.6 million recorded in 2022.
  • Peak YoY movement for Common Equity: skyrocketed 326.48% in 2021, then plummeted 77.57% in 2025.
  • A 5-year view of Common Equity shows it stood at $408.4 million in 2021, then rose by 14.47% to $467.4 million in 2022, then grew by 18.56% to $554.2 million in 2023, then crashed by 48.01% to $288.1 million in 2024, then tumbled by 77.57% to $64.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $64.6 million in Q4 2025, $115.4 million in Q3 2025, and $157.4 million in Q2 2025.